New drug may offer safer CMV prevention for kidney transplant patients
Prevention
Not yet recruiting
This study tests if letermovir works as well as valganciclovir in preventing CMV infection in 300 kidney transplant patients who are CMV-positive. Both drugs are given for 90 days after transplant. Researchers will also check if letermovir is easier to tolerate and how long it ta…
Phase: PHASE4 • Sponsor: Elisabeth Kincaide • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC